Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of FOLFIRI + aflibercept after anti-EGFR failure in colorectal cancer
jRCTs011190006Phase 2Completed
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- Jan 2020
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Hokkaido Gastrointestinal Cancer Study Group. Primary endpoint: Progression-free survival rate at 6 months. Started Jan 2020; status: completed.
02
Drugs
afliberceptirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs011190006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011190006.